Rats were randomly assigned to sham surgery, myocardial infarction with saline, or myocardial infarction followed by combined drug treatment, with nine animals in each group. Rats in the combination group received bevantolol at 10.5 mg/kg and tandospirone at 3.15 mg/kg by intragastric administration for seven days. Infarcted controls received 5 mL/kg of physiological saline. The doses were converted from human doses through a body-surface-area method, and tissues were collected after the final administration.

Investigators assessed infarct size using TTC/Evans blue staining. In this method, tissue unstained by Evans blue represented the ischemic area, while tissue not stained by TTC within that area represented infarction. Quantitative histological analyses used three biological replicates per group. Hematoxylin and eosin staining showed disorganized myocardium, inflammatory-cell infiltration, collagenous fibers, and visible scar in infarcted control rats. These abnormalities were less pronounced in rats receiving the combination, supporting the observation that combined treatment mitigated myocardial pathological damage after infarction.

Masson staining was used to quantify fibrosis through the collagen volume fraction, defined as the proportion of positively stained collagen area relative to total tissue area. Collagen volume fraction was higher after infarction than in sham-operated rats and lower with combined treatment than in saline-treated infarcted controls. TUNEL staining, which detects DNA fragmentation rather than apoptosis specifically, also showed a higher proportion of positive cells after infarction and a lower proportion following combined treatment. The investigators cautioned that TUNEL-positive cells can reflect multiple programmed cell-death pathways, including pyroptosis, so the assay did not quantify the separate contributions of apoptosis and pyroptosis to cardiomyocyte loss.

Enzyme-linked immunosorbent assays used six biological replicates per group to measure serum creatine kinase-MB and cardiac troponin I, serum and myocardial-tissue concentrations of interleukin-1β and interleukin-18, and myocardial-tissue concentrations of interleukin-1β and interleukin-18. Compared with sham-operated animals, infarcted controls had higher concentrations of the myocardial injury markers and inflammatory cytokines. The combined-treatment group had lower concentrations of all six measured analyte-location combinations than infarcted controls. Quantitative reverse-transcription polymerase chain reaction and Western blotting likewise showed higher myocardial interleukin-1β and interleukin-18 messenger RNA and protein expression after infarction and lower expression with the combination.

The investigators next examined NLRP3, cleaved Caspase-1, and the N-terminal domain of gasdermin D, designated GSDMD-N. Immunohistochemical staining, qRT-PCR, and Western blotting showed increased expression of these markers in infarcted controls relative to sham-operated rats and decreased expression in the combination group. These findings demonstrate lower molecular-marker expression following combined treatment; they do not, by themselves, prove that the treatment directly inhibited the pathway or that pathway suppression mediated the histological effects.

The study also assessed the precursor proteins pro-Caspase-1 and full-length GSDMD. Both were elevated after myocardial infarction. Their abundance was numerically lower in the combination group, but the differences from infarcted controls were not significant. By contrast, the ratios of cleaved Caspase-1 to pro-Caspase-1 and GSDMD-N to full-length GSDMD increased after infarction and were significantly reduced by combined treatment. The authors interpreted this pattern as consistent with less cleavage and activation of Caspase-1 and GSDMD rather than a major change in precursor-protein abundance.

Several limitations constrain the findings. The experiment did not include myocardial-infarction groups treated with bevantolol or tandospirone alone, so it cannot show that the combination was more effective than either drug or that the agents interacted synergistically. It also did not measure cardiac function, survival, or outcomes beyond the one-week treatment period, and it did not test post-infarction anxiety-like or depression-like behavior. Alternative stress-modulating drugs were not evaluated. The mechanistic interpretation remains bounded by the absence of a validated NLRP3-specific inhibitor or activator and definitive functional pyroptosis assays.

Cell-type-specific co-staining was also not performed, so the experiment could not identify which myocardial or inflammatory cell populations generated the pathway signals. These results therefore support an association between combined bevantolol and tandospirone treatment, reduced myocardial injury markers, and lower NLRP3/Caspase-1/GSDMD-associated marker expression in a short-term male rat infarction model. They do not demonstrate human clinical efficacy, long-term functional benefit, or a causal pathway mechanism.

Subject of Research: Short-term rat myocardial infarction study of bevantolol plus tandospirone and NLRP3/Caspase-1/GSDMD-associated markers

Article Title: Protection of beta-blocker and 5-hydroxytryptamine 1A receptor agonist on myocardial ischemia injury in rats by regulating the NLRP3/Caspase-1/GSDMD pathway

Article References: Chen, H., Li, Y., Liu, M., Chi, Y., & Zhang, L. (2026). Protection of beta-blocker and 5-hydroxytryptamine 1A receptor agonist on myocardial ischemia injury in rats by regulating the NLRP3/Caspase-1/GSDMD pathway. PLOS One, 21(10), e0360695. https://doi.org/10.1371/journal.pone.0360695

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360695

Keywords: rat myocardial infarction, bevantolol, tandospirone, beta-blocker, 5-HT1A receptor agonist, NLRP3 inflammasome, Caspase-1, GSDMD, myocardial inflammation, pyroptosis, Protection, hydroxytryptamine

Pyroptosis is not an ordinary death. It is a programmed, highly inflammatory form of cell suicide that serves as an alarm system for the immune system. It is triggered when pathogen-associated or danger-associated molecular patterns are detected in the cytosol, the fluid interior of the cell. Upon sensing these threats, caspase-1 in humans and mice, along with caspase-4, caspase-5 in humans and caspase-11 in mice, cleaves a protein called gasdermin D, or GSDMD. This cleavage releases the N-terminal fragment of GSDMD, which migrates to the cell membrane and oligomerizes into pores. These pores disrupt the osmotic balance of the cell, allowing water to rush in, causing the cell to swell, burst and spill its inflammatory contents, including the potent cytokine interleukin-1β, into the surrounding tissue.

While this fiery demise is useful for containing infection, overactive pyroptosis is a driver of disease. Excessive pyroptotic cell death has been implicated in atherosclerosis, arthritis, Alzheimer’s disease, HIV and various types of cancer. This has made the inflammatory caspases attractive drug targets, and caspase inhibitors have captured the attention of scientists and clinicians alike. Yet developing safe and clinically effective caspase inhibitors has proven remarkably difficult. The central problem is selectivity. Caspases are a family of proteases with overlapping substrate preferences, which makes it difficult to inhibit one member without affecting others. Many existing inhibitors block caspases involved in both pyroptosis and apoptosis, the quiet, non-inflammatory form of cell death that is essential for development and immunity. Worse, inhibiting caspase-8 can sensitize cells to necroptosis, another damaging form of cell death, potentially trading one pathology for another.

To escape this trap, Groborz and colleagues took a rational, chemistry-driven approach. They exploited the known substrate preferences of individual caspases to synthesize a library of roughly one hundred tetrapeptides, each attached to an acyloxymethyl ketone, or AOMK, group. These reactive chemical groups allow the tetrapeptides to bind covalently and irreversibly to the active sites of their target caspases, ensuring durable inhibition. From this library, several candidates emerged that suppressed cell death driven by caspase-1, caspase-4 and caspase-11 while leaving staurosporine-induced apoptosis untouched. One of the most potent, named KGR-3, stood out as a strong inhibitor of caspase-1 and caspase-4.

The detailed characterization of KGR-3 revealed just how precisely it worked. The compound blocked pyroptosis by preventing the cleavage of GSDMD, thereby stopping pore formation at its source. It also attenuated the release of interleukin-1β and lactate dehydrogenase, a standard marker of membrane rupture, in response to activation of the NLRP3 and NLRP1 inflammasomes, the multiprotein complexes that activate caspase-1. Crucially, KGR-3 did not interfere with hallmarks of apoptosis such as caspase-1-induced blebbing or caspase-3 cleavage, nor did it affect necrosis triggered by listeriolysin O, a bacterial toxin. Cells treated with KGR-3 not only avoided death; their swelling and lysis were suppressed and they continued to grow and divide. The inhibitor appeared to grant cells a genuine reprieve rather than merely delaying the inevitable.

Yet a puzzling observation threatened to undermine the whole story. KGR-3 and its chemical siblings showed limited permeability in healthy cells, meaning they should not have been able to reach the intracellular caspases they so effectively inhibited. This paradox led the authors to a bold hypothesis: pyroptosis itself facilitates inhibitor uptake. Like a Trojan horse being wheeled through the gates of a besieged city, the caspase inhibitors were exploiting the very pores formed during pyroptosis to slip inside and reach the caspases driving the process. To test this idea, the researchers used propidium iodide and YOYO-1, two small fluorescent molecules that normally cannot cross intact membranes. Both entered cells in a GSDMD-dependent manner, providing strong evidence that gasdermin pores admit small molecules from the outside.

The story became even more sophisticated when the researchers examined what happened to the membrane damage inflicted along the way. In KGR-3-treated cells, GSDMD-induced membrane injury was repaired by the endosomal sorting complexes required for transport, known as the ESCRT machinery. This repair system is a conserved cellular mechanism that seals small membrane wounds. When the researchers expressed dominant-negative versions of the ESCRT proteins VPS4A and CHMP3, KGR-3 lost its protective effect, and pyroptosis proceeded. This finding challenges the simple binary view of pyroptosis as an irreversible commitment to death. Instead, it suggests a pharmacologically accessible window between the initiation of pyroptosis and final lysis, a period during which GSDMD pores disrupt the membrane enough to admit the drug, but not so extensively that repair by ESCRT becomes impossible. Recent research has independently highlighted the reversibility of GSDMD pore formation and shown that ESCRT can limit pyroptosis and cytokine secretion after inflammasome activation, lending further support to this model.

There is also an elegant pharmacological lesson hidden in the poor permeability of these compounds. In traditional drug development, limited cell permeability is considered a weakness. Here, it becomes a feature. Because the inhibitors can only enter cells whose membranes have already been breached by gasdermin pores, they are restricted to unhealthy cells, those actively undergoing pyroptosis, and are excluded from healthy neighbors. This built-in targeting mechanism could limit the off-target effects that have plagued broader caspase inhibitors, offering a new design principle: drugs need not always be membrane permeable if the disease state itself creates the doorway. The study thus overturns the conventional assumption that any drug aimed at an intracellular target must be able to cross an intact plasma membrane.

Translating the concept into animals required further chemical refinement. KGR-3 itself showed limited efficacy in vivo, but another tetrapeptide from the library, KGR-53, proved more promising. It was selected for animal testing because of its potent inhibition of caspase-11, a key mediator of endotoxic shock induced by lipopolysaccharide in mice. Because negatively charged compounds are transported inefficiently through GSDMD pores, the team designed a derivative called KGR-53P that lacks a negative charge. This optimized compound inhibited GSDMD cleavage and blocked the caspase-1- and caspase-11-dependent secretion of interleukin-1β and interleukin-18, while leaving both intrinsic and extrinsic apoptosis intact. In a mouse model of endotoxic shock, a condition driven by runaway caspase-11 activity, this selectivity could prove decisive.

The work is not without caveats, as Henry and O’Neill note in their highlight. First, the entry of KGR-3 through GSDMD pores has not been directly visualized. Although the GSDMD-dependent uptake of propidium iodide and YOYO-1 strongly implies that the pores serve as entry routes for small molecules, attempts to image KGR-3 itself failed because fluorescent tagging compromised the compound’s potency, permeability or toxicity. Second, KGR-53 showed evidence of liver toxicity in vivo, and it remains unclear whether this toxicity stems from the AOMK chemistry, an off-target effect or an entirely different mechanism. These open questions will shape the next phase of research. Even so, the conceptual advance is considerable. If the window between pyroptosis initiation and lysis can be reliably exploited, a new class of anti-inflammatory drugs could emerge that intervene only where inflammation is already burning, leaving healthy tissue untouched. The gates that pyroptosis opens may, in the end, become the route by which medicine tames it.

Subject of Research: Selective inflammatory caspase inhibitors that enter cells through gasdermin D pores to inhibit pyroptosis

Article Title: A Trojan horse story: does pyroptosis open the gates to its own inhibition?

Article References: Henry, Ó. C., & O’Neill, L. A. J. (2026). A Trojan horse story: does pyroptosis open the gates to its own inhibition?. Cell Research. https://doi.org/10.1038/s41422-026-01302-z

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01302-z

Keywords: pyroptosis, gasdermin D, inflammatory caspases, caspase-1, caspase-11, GSDMD, ESCRT, inflammasome, cell death, innate immunity, drug design, inflammation

The research team, led by Zheng Li, Zhenan Zhang, Qiancheng Zhao, Zhenpeng Zhu and senior authors Wei Yu and Qian Zhang, combined spatial transcriptomics, single-cell RNA sequencing, immunohistochemistry in fifty patients, functional cell-culture perturbations and mouse genetics to map what they call a macrophage-orchestrated pyroptosis–senescence–club axis in the human prostate. Spatial transcriptomics integrates fourteen tissue sections from public datasets covering normal prostate, untreated benign prostatic hyperplasia and hyperplasia after 5-alpha-reductase inhibitor therapy, retaining 46,176 tissue-covered spots after quality control. By transferring labels from published single-cell references, the team resolved twelve major cell classes and could ask not just which cells were present but where they sat relative to one another, and which ligand–receptor pairs were firing across those microscopic neighborhoods.

The compositional shifts they documented were substantial. In untreated hyperplasia, smooth muscle cells expanded from 13.9 percent of the mapped tissue to 31.6 percent, myofibroblasts surged from 0.47 to 17.3 percent, and luminal epithelium dominated at nearly 40 percent. After 5-alpha-reductase inhibitor exposure, however, the epithelial landscape tilted: the luminal fraction fell to 34.5 percent while club cells, a secretory lineage marked by SCGB1A1 expression, more than doubled from 5.59 to 13.5 percent. Macrophages and B cells also crept upward. Spatial pseudotime reconstruction, rooted in basal-enriched tissue domains, showed that treated samples bifurcated into two transcriptional arms, one resembling a drug-remodeled state enriched for senescence and chemokine programs, and another that persisted near the untreated terminal state, carrying anti-apoptotic and pro-growth signatures the authors describe as tolerance-like.

The pivotal discovery concerns how macrophages are drawn in and then detonated. Under drug pressure, luminal epithelial cells ramped up secretion of macrophage migration inhibitory factor, or MIF, and the chemokine CXCL12. In Transwell chemotaxis assays, conditioned medium from finasteride-treated epithelial cells boosted macrophage migration roughly 3.6-fold using a prostate cancer-derived line and about 4.1-fold using primary luminal epithelial cells isolated fresh from surgical specimens. Blocking MIF or its receptor CD74, or CXCL12 or its receptor CXCR4, each partially curtailed migration, and dual blockade pushed migration back toward baseline. Critically, only the MIF–CD74 axis, not CXCL12–CXCR4, triggered pyroptosis itself, the inflammatory form of cell death in which the NLRP3 inflammasome activates caspase-1 and the pore-forming protein gasdermin D, or GSDMD, ruptures the cell and spills IL-1β, IL-18 and the danger signal HMGB1 into the tissue.

Patient tissue told the same story. Immunohistochemistry across 25 untreated and 25 independently drug-treated patients showed significantly increased CD68 macrophage staining and GSDMD-N, the cleaved active fragment of gasdermin D, in the treated group, with higher macrophage strata aligning with higher pyroptosis grades. Multiplex immunofluorescence and nearest-neighbor distance analysis confirmed that MIF-positive epithelial regions sat measurably closer to CD74- and GSDMD-positive macrophages than background geometry would predict, and that HMGB1-rich pyroptotic macrophages clustered near AGER-positive epithelium, arguing the signaling hotspots were genuine anatomical structures rather than artifacts of mixed measurement spots.

What happens next in the cascade is the senescence step. Conditioned medium from pyroptotic macrophages increased senescence-associated beta-galactosidase positivity in luminal epithelial cells three- to four-fold, drove a pronounced accumulation of cells in the G1 phase of the cell cycle, halved DNA synthesis as measured by EdU incorporation, and elevated the senescence-associated secretory phenotype, with IL-1α, IL-6, IL-8, TNF and MCP-1 rising two- to four-fold. Neutralizing HMGB1 largely reversed all of these effects, whereas blocking IL-1β or IL-18 did little. Co-immunoprecipitation identified AGER, also known as RAGE, as the functional epithelial receptor for HMGB1, and genetic knockdown of AGER rescued the senescence phenotype while receptor overexpression amplified it in an HMGB1-dependent fashion. In patient tissues, both AGER and the senescence marker p16 were significantly elevated after drug treatment.

The final twist is the lineage reprogramming. When the researchers co-cultured recipient luminal cells with senescent primary luminal cells, the senescent cells paracrinely pushed their neighbors toward a club-like identity, increasing SCGB1A1, SCGB3A1 and lactotransferrin while suppressing the androgen receptor, and simultaneously raising the apoptotic threshold through Bcl-2 upregulation and reduced cleaved caspase-3. Knocking down NOTCH1 in the recipient cells partially reversed this conversion, positioning Notch as a druggable effector node downstream of the senescence signal. Patient biopsies corroborated the shift in vivo, showing increased SCGB1A1, reduced androgen receptor and enhanced Notch staining after 5-alpha-reductase inhibitor therapy. The authors interpret the resulting state as a low-proliferation, high-survival adaptation that blunts the gland-shrinking effect the drugs are meant to achieve.

Causal support came from the mouse model. In a castration/testosterone-induced model of prostatic hyperplasia designed to standardize the androgenic background, 5-alpha-reductase inhibitor treatment reduced the prostate index relative to untreated hyperplasia, as expected, but simultaneously expanded the fraction of pyroptotic macrophages from about 21 percent to 37 percent of live tissue macrophages, as quantified by active caspase-1 staining. When the researchers deleted Gsdmd, the pyroptotic fraction collapsed to under 10 percent, senescence and club-like transcriptional programs were attenuated, and prostate enlargement fell further than with the drug alone. Bulk RNA sequencing of the mouse prostates mirrored the human findings, with drug-treated glands enriching pyroptotic inflammatory, luminal-senescence and club-like secretory signatures, all of which were dampened by gasdermin D loss.

The translational payoff is a 13-gene pyroptosis–macrophage signature, dubbed PM-13 and comprising NLRP3, CASP1, CSF1R, CD68, SOD2, IL27, IRF1, CCL2, IL12B, OAS2, CCL7, NLRP2 and TNF, which stratified resistant from responsive patients in an independent longitudinal cohort with area-under-the-curve values of 0.832 at follow-up and 0.858 at baseline. The authors propose a sequential intervention strategy, upstream first and downstream next: de-ignite the cascade by targeting MIF–CD74, dampen the danger signal by blocking HMGB1–AGER or inhibiting GSDMD, and then reshape the epithelium through moderated Notch tuning. Because HMGB1 is detectable in blood and urine, the framework even suggests pharmacodynamic monitoring. The team is candid about limitations, including the cross-sectional nature of the spatial cohort, redundancy among danger signals such as ATP and S100-family proteins, the partial reversal achieved by Notch inhibition alone, and the fact that the mouse model uses castration plus testosterone rather than directly phenocopying clinical monotherapy. Even so, the study reframes drug resistance in benign prostatic hyperplasia not as a failure of hormone blockade but as a programmable immune–epithelial adaptation, and it hands clinicians four concrete molecular switches with which to intervene before a patient’s prostate outlasts the prescription.

Subject of Research: Macrophage pyroptosis-driven epithelial senescence and lineage reprogramming in benign prostatic hyperplasia treated with 5-alpha-reductase inhibitors

Article Title: Macrophage pyroptosis drives luminal senescence and club-cell reprogramming in 5α-reductase inhibitor-treated prostatic hyperplasia

Article References: Li, Z., Zhang, Z., Zhao, Q., Zhu, Z., Yang, K., Meng, Y., Zhang, Q., & Yu, W. (2026). Macrophage pyroptosis drives luminal senescence and club-cell reprogramming in 5α-reductase inhibitor-treated prostatic hyperplasia. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01864-3

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01864-3

Keywords: benign prostatic hyperplasia, 5-alpha-reductase inhibitors, macrophage pyroptosis, GSDMD, HMGB1–AGER signaling, MIF–CD74 axis, cellular senescence, club-cell reprogramming, spatial transcriptomics, single-cell RNA sequencing, Notch signaling, PM-13 gene signature

The research team built its case using a conditional knockout mouse in which TDP-43 was deleted specifically from neurons. Animals carrying floxed TDP-43 alleles crossed with Map2-CreERT2 drivers received tamoxifen at eight weeks of age, stripping the protein from cortical and spinal neurons. Within weeks, the mice developed a striking ALS-like syndrome: rotarod performance began declining by day 12 after induction and fell significantly by day 18, forelimb grip strength collapsed by day 24, and by day 28 the animals were near moribund, with profound hindlimb muscle atrophy, flaccid tails, and dramatically shortened survival compared with controls. Histochemical staining of the motor cortex and lumbar spinal cord confirmed the behavioral picture, revealing marked neuronal loss and atrophy in precisely the regions that control movement.

But the most revealing data came from metabolism. L-lactate, the end product of anaerobic glycolysis, accumulated to significantly elevated levels in the motor cortex of TDP-43 knockout mice at the terminal stage of disease, and ALDOA messenger RNA and protein were both upregulated in the same tissue. Immunofluorescence showed that the excess ALDOA colocalized with neurons, placing the metabolic shift squarely inside the cells that were dying. In parallel experiments, the researchers knocked down TDP-43 in NSC-34 motor neuron-like cells and observed the same triad: damaged mitochondria, evidenced by reduced mitochondrial membrane potential; increased glucose uptake measured with the fluorescent analog 2-NBDG; and elevated intracellular and secreted lactate, accompanied by reduced cell viability.

These results make biological sense in the context of neuronal energetics. Healthy neurons preferentially rely on mitochondrial aerobic oxidation, but when mitochondria falter or the tricarboxylic acid cycle is impaired, cells compensate by shunting glucose through anaerobic glycolysis—a less efficient pathway that demands heightened glucose uptake and produces lactate as a byproduct. The study’s authors argue that TDP-43 loss triggers precisely this compensatory shift, but in a maladaptive, runaway form. What may begin as an emergency energy measure becomes a persistent high-lactate environment that promotes acidosis, oxidative stress, and inflammatory signaling, ultimately compounding the very neuronal injury it was meant to offset.

The mechanistic linchpin connecting glycolysis to cell death is the NLRP3 inflammasome. Prior work had shown that elevated ALDOA activity in macrophages enhances glycolysis, suppresses AMPK signaling, and activates NLRP3, and that NLRP3-mediated pyroptosis exacerbates neuroinflammation and motor neuron degeneration in ALS models. The new study closes the loop. In the motor cortex of TDP-43 knockout mice, the researchers detected significant upregulation of NLRP3, cleaved caspase-1, and the pore-forming fragment of gasdermin D (N-GSDMD)—the molecular signature of pyroptosis—alongside elevated IL-1β. Immunofluorescence confirmed that NLRP3 and N-GSDMD colocalized with neuronal markers, indicating that the pyroptotic machinery was firing inside motor neurons themselves, not merely in surrounding glia.

To test whether ALDOA was a cause rather than a bystander, the team turned to aldometanib, a selective ALDOA inhibitor that blocks the enzyme’s catalysis of fructose-1,6-bisphosphate. In TDP-43 cKO mice given oral aldometanib four times per week beginning one week after TDP-43 deletion, cortical lactate levels fell sharply, the abundance of NLRP3, caspase-1, N-GSDMD, and IL-1β dropped, and Nissl staining revealed a significantly higher count of surviving neurons in the motor cortex. Most strikingly, treated mice lived a median of 33 days after induction compared with 28 days for untreated knockouts—a meaningful extension in such an aggressive model. Treated animals also retained spontaneous movement at a stage when untreated littermates were moribund, although formal rotarod and wire-hang scores did not reach statistical significance.

The cellular experiments reinforced the pharmacological findings. A 24-hour exposure to 1 nanomolar aldometanib significantly reduced glucose uptake, intracellular and extracellular lactate, and the activation of the NLRP3-caspase-1-GSDMD axis in TDP-43-deficient NSC-34 cells, while restoring cell viability and reducing propidium iodide–positive cell death. The authors emphasize that this is the first assessment of aldometanib’s neuroprotective potential; the compound had previously been studied mainly in oncology contexts. By positioning ALDOA as an upstream node in the pathogenic cascade—upstream of both the metabolic collapse and the inflammatory cell death it triggers—the work identifies an intervention point earlier than current preclinical strategies that target mitochondria or lactate downstream.

The study also speaks to the peculiar complexity of TDP-43 biology. Earlier work on mutant TDP-43 proteins such as M337V had linked the protein to ALDOA through enhanced binding, and some cell models expressing mutant TDP-43 showed time-dependent decreases in glycolytic enzymes. The new findings demonstrate that loss of TDP-43 function, by contrast, upregulates ALDOA specifically in the motor cortex, underscoring that toxic gain-of-function and loss-of-function mechanisms can push metabolic networks in opposite directions. The model itself carries technical advantages: unlike astrocyte- or microglia-specific TDP-43 deletions, which the authors note produce mild or no motor phenotypes, neuronal deletion recapitulates hallmark ALS features rapidly and without sex bias, reinforcing the idea that neuronal TDP-43 is the critical determinant of disease.

Caveats remain. Direct evidence for ALDOA dysregulation in human ALS tissue or biofluids is still lacking, and the authors call for validation in post-mortem samples and patient-derived iPSC motor neurons. Aldometanib’s pharmacokinetics, blood–brain barrier penetration, and selectivity relative to other aldolase isoforms also require characterization, and the absence of genetic ALDOA knockdown data leaves its precise causal contribution incompletely resolved. Even so, the identification of a glycolysis–inflammasome–pyroptosis axis in ALS reframes the disease as a metabolic-inflammatory disorder and raises the tantalizing possibility that taming an ancient metabolic enzyme could buy motor neurons—and patients—precious time.

Subject of Research: The role of the glycolytic enzyme ALDOA in driving NLRP3/GSDMD-mediated pyroptosis and motor neuron degeneration in TDP-43-deficient ALS.

Article Title: ALDOA Promotes Glycolysis and NLRP3/GSDMD Pyroptosis to Accelerate ALS Progression

Article References: Yan, K., Jiang, Y., Yong, Y., Zhang, T., Zhang, N., Zeng, Q., Gong, X., Meng, L., Bi, F., & Liu, Y. (2026). ALDOA Promotes Glycolysis and NLRP3 / GSDMD Pyroptosis to Accelerate ALS Progression. Annals of Clinical and Translational Neurology, 13(9), 1903-1918. https://doi.org/10.1002/acn3.70372

Image Credits: AI Generated

DOI: 10.1002/acn3.70372

Keywords: ALS, TDP-43, ALDOA, glycolysis, NLRP3 inflammasome, pyroptosis, GSDMD, aldometanib, neuroinflammation, motor neurons, lactate, mitochondrial dysfunction